Advertisement

Strahlentherapie und Onkologie

, Volume 195, Issue 4, pp 289–296 | Cite as

Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study

  • Paul Rogowski
  • Stephan Schönecker
  • Montserrat Pazos
  • Daniel Reitz
  • Michael Braun
  • Martin Pölcher
  • Claus Hanusch
  • Rachel Wuerstlein
  • Nadia Harbeck
  • Sven Mahner
  • Claus Belka
  • Stefanie CorradiniEmail author
Original Article

Abstract

Background and purpose

Due to the rarity of male breast cancer (male BC), no consensus has been reached regarding the most appropriate curative treatment strategy. The objective of the present observational study was to identify patient and tumor characteristics and assess the role of radiotherapy (RT) in clinical practice.

Methods

Between 1998 and 2014, data of male BC patients treated at two breast centers were consecutively collected and retrospectively analyzed. Patients were stratified based on the addition of adjuvant RT. Data on overall survival (OS) and local recurrence-free survival (LRFS) were estimated with the Kaplan–Meier method and compared by the log-rank test.

Results

A consecutive cohort of 58 male BC patients was evaluated. Median follow-up was 56 months. Twenty-one patients (36.2%) received adjuvant RT. Overall, patients undergoing postoperative RT were characterized by more high-risk features. Patients receiving postoperative RT had significantly more frequently a high UICC stage (50 vs. 9.7% UICC III, p = 0.018) and positive lymph nodes as compared to patients undergoing surgery alone (65 vs. 34.4% pN+, p = 0.046). Accordingly, there was a higher proportion of patients receiving axillary lymph node dissection in the RT group (71.4 vs. 35.6%). Mastectomy was performed in 31/37 (86.1%) in the surgery group as compared to 14/21 (66.7%) in patients receiving postoperative RT. In addition, RT patients were more likely to receive endocrine therapy (78.9 vs. 39.3%, p = 0.016). Outcome was not significantly different between the groups (5-year LRFS: 89.8 vs. 80.0%, p = 0.471 and 5‑year OS 88.4 vs. 88.9%, p = 0.819).

Conclusion

The present observational study evaluated the pattern of care in male BC patients treated in clinical practice. Due to its rarity, randomized clinical trials are unlikely and male BC remains an entity with a poor evidence base. Nevertheless, RT remains a crucial component of the multidisciplinary treatment strategy in male BC.

Keywords

Male breast cancer Radiotherapy Local control Survival Observational study Outcome 

Adjuvante Radiotherapie beim Mammakarzinom des Mannes in der klinischen Praxis: Eine Beobachtungsstudie

Zusammenfassung

Hintergrund und Zielsetzung

Das Mammakarzinom (MC) des Mannes ist eine seltene Erkrankung. Bis heute wurde noch kein Konsens hinsichtlich der optimalen kurativen Behandlungsstrategie erzielt. Das Ziel dieser Beobachtungsstudie ist es, Patienten- und Tumormerkmale zu identifizieren und die Rolle der Radiotherapie (RT) in der klinischen Praxis zu beurteilen.

Methoden

Daten von Männern mit MC wurden analysiert, die zwischen 1998 und 2004 in zwei Brustzentren behandelt wurden. Die eingeschlossenen Patienten waren entweder adjuvant bestrahlt worden oder nicht. Gesamtüberleben (OS) und lokal-rezidivfreies Überleben (LRFS) wurden mit der Kaplan-Meier-Methode bestimmt und mit dem Log-Rank-Test verglichen.

Ergebnisse

Eine Kohorte von 58 männlichen MC-Patienten wurde analysiert. Die mediane Beobachtungszeit betrug 56 Monate. Eine adjuvante RT erhielten 21 Patienten (36,2 %). Insgesamt wiesen Patienten, die postoperativ bestrahlt wurden, mehr Hochrisikofaktoren auf. Sie hatten im Vergleich zu den nur operierten Patienten signifikant häufiger ein höheres UICC-Stadium (UICC III bei 50 vs. 9,7 %; p = 0,018) und befallene Lymphknoten (pN+ in 65 vs. 34,4 %; p = 0,046). Dementsprechend erhielt in der RT-Gruppe ein größerer Anteil der Patienten eine axilläre Lymphknotendissektion (71,4 vs. 35,6 %). Eine Mastektomie wurde bei 31/37 Patienten (86,1 %) in der Gruppe mit alleiniger Operation durchgeführt, verglichen mit 14/21 Patienten (66,7 %), die eine adjuvante RT erhielten. Außerdem wurden Patienten in der RT-Gruppe häufiger mit einer zusätzlichen endokrinen Therapie behandelt (78,9 vs. 39,3 %; p = 0,016). Das Outcome war zwischen den Gruppen nicht signifikant unterschiedlich (LRFS und OS nach 5 Jahren 89,8 vs. 80,0 %; p = 0,471 bzw. 88,4 vs. 88,9 %; p = 0,819).

Schlussfolgerung

Die vorliegende Beobachtungsstudie untersuchte das Behandlungskonzept von männlichen Patienten im klinischen Alltag. Aufgrund der Seltenheit der Erkrankung sind randomisierte klinische Studien unwahrscheinlich und das MC des Mannes bleibt eine Entität mit schlechter Evidenzlage. Die RT bleibt ein wichtiger Bestandteil der multidisziplinären Behandlungsstrategie.

Schlüsselwörter

Mammakarzinom des Mannes Strahlentherapie Lokale Kontrolle Überleben Beobachtungsstudie Outcome 

Notes

Conflict of interest

P. Rogowski, S. Schönecker, M. Pazos, D. Reitz, M. Braun, M. Pölcher, C. Hanusch, R. Wuerstlein, N. Harbeck, S. Mahner, C. Belka, and S. Corradini declare that they have no competing interests.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30.  https://doi.org/10.3322/caac.21387 CrossRefGoogle Scholar
  2. 2.
    Sanguinetti A, Polistena A, Lucchini R, Monacelli M, Galasse S, Avenia S, Triola R, Bugiantella W, Cirocchi R, Rondelli F, Avenia N (2016) Male breast cancer, clinical presentation, diagnosis and treatment: twenty years of experience in our breast unit. Int J Surg Case Rep 20:8–11.  https://doi.org/10.1016/j.ijscr.2016.02.004 CrossRefGoogle Scholar
  3. 3.
    Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28(2):232–239.  https://doi.org/10.1200/JCO.2009.23.8162 CrossRefGoogle Scholar
  4. 4.
    Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer 101(1):51–57.  https://doi.org/10.1002/cncr.20312 CrossRefGoogle Scholar
  5. 5.
    Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367(9510):595–604.  https://doi.org/10.1016/S0140-6736(06)68226-3 CrossRefGoogle Scholar
  6. 6.
    Losurdo A, Rota S, Gullo G, Masci G, Torrisi R, Bottai G, Zuradelli M, Gatzemeier W, Santoro A (2017) Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature. Critical reviews in oncology. Hematology 113:283–291.  https://doi.org/10.1016/j.critrevonc.2017.03.013 Google Scholar
  7. 7.
    Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schroder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litiere S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH (2018) Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 29(2):405–417.  https://doi.org/10.1093/annonc/mdx651 Google Scholar
  8. 8.
    Iorfida M, Bagnardi V, Rotmensz N, Munzone E, Bonanni B, Viale G, Pruneri G, Mazza M, Cardillo A, Veronesi P, Luini A, Galimberti V, Goldhirsch A, Colleoni M (2014) Outcome of male breast cancer: a matched single-institution series. Clin Breast Cancer 14(5):371–377.  https://doi.org/10.1016/j.clbc.2014.02.008 CrossRefGoogle Scholar
  9. 9.
    Foerster R, Foerster FG, Wulff V, Schubotz B, Baaske D, Wolfgarten M, Kuhn WC, Rudlowski C (2011) Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer 11(1):335–335.  https://doi.org/10.1186/1471-2407-11-335 CrossRefGoogle Scholar
  10. 10.
    Kiluk JV, Lee MC, Park CK, Meade T, Minton S, Harris E, Kim J, Laronga C (2011) Male breast cancer: management and follow-up recommendations. Breast J 17(5):503–509.  https://doi.org/10.1111/j.1524-4741.2011.01148.x CrossRefGoogle Scholar
  11. 11.
    Sroufe RL, Schwartz D, Rineer J, Choi K, Rotman M, Schreiber D (2012) A population-based study of the impact of post-mastectomy radiation on survival for male breast cancer. J Radiat Oncol 1(4):337–345.  https://doi.org/10.1007/s13566-012-0062-7 CrossRefGoogle Scholar
  12. 12.
    Rushton M, Kwong A, Visram H, Graham N, Petrcich W, Dent S (2014) Treatment outcomes for male breast cancer: a single-centre retrospective case-control study. Curr Oncol 21(3):e400–407.  https://doi.org/10.3747/co.21.1730 CrossRefGoogle Scholar
  13. 13.
    Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24(6):1434–1443.  https://doi.org/10.1093/annonc/mdt025 CrossRefGoogle Scholar
  14. 14.
    Yu E, Suzuki H, Younus J, Elfiki T, Stitt L, Yau G, Vujovic O, Perera F, Lock M, Tai P (2012) The impact of post-mastectomy radiation therapy on male breast cancer patients—a case series. Int J Radiat Oncol Biol Phys 82(2):696–700.  https://doi.org/10.1016/j.ijrobp.2011.01.010 CrossRefGoogle Scholar
  15. 15.
    Fields EC, Dewitt P, Fisher CM, Rabinovitch R (2013) Management of male breast cancer in the united states: a surveillance, epidemiology and end results analysis. Int J Radiat Oncol Biol Phys 87(4):747–752.  https://doi.org/10.1016/j.ijrobp.2013.07.016 CrossRefGoogle Scholar
  16. 16.
    Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R, Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bliss J, Buyse M, Cameron D, Carrasco E, Clarke M, Correa C, Coates A, Collins R, Costantino J, Cutter D, Cuzick J, Darby S, Davidson N, Davies C, Davies K, Delmestri A, Di Leo A, Dowsett M, Elphinstone P, Evans V, Ewertz M, Gelber R, Gettins L, Geyer C, Goldhirsch A, Godwin J, Gray R, Gregory C, Hayes D, Hill C, Ingle J, Jakesz R, James S, Kaufmann M, Kerr A, MacKinnon E, McGale P, McHugh T, Norton L, Ohashi Y, Paik S, Pan HC, Perez E, Peto R, Piccart M, Pierce L, Pritchard K, Pruneri G, Raina V, Ravdin P, Robertson J, Rutgers E, Shao FY, Swain S, Taylor C, Valagussa P, Viale G, Whelan T, Winer E, Wang Y, Wood W (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 378(9804):1707–1716.  https://doi.org/10.1016/S0140-6736(11)61629-2 CrossRefGoogle Scholar
  17. 17.
    McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S, Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bergsten Nordström E, Bliss J, Burrett JA, Buyse M, Cameron D, Carrasco E, Clarke M, Coleman R, Correa C, Coates A, Collins R, Costantino J, Cutter D, Cuzick J, Darby S, Davidson N, Davies C, Davies K, Delmestri A, Di Leo A, Dowsett M, Elphinstone P, Evans V, Ewertz M, Forbes J, Gelber R, Gettins L, Geyer C, Gianni L, Gnant M, Goldhirsch A, Godwin J, Gray R, Gregory C, Hayes D, Hill C, Ingle J, Jakesz R, James S, Janni W, Kaufmann M, Kerr A, Liu H, MacKinnon E, Martín M, McGale P, McHugh T, Morris P, Norton L, Ohashi Y, Paik S, Pan HC, Perez E, Peto R, Piccart M, Pierce L, Pritchard K, Pruneri G, Raina V, Ravdin P, Robertson J, Rutgers E, Shao YF, Sparano J, Swain S, Taylor C, Valagussa P, Viale G, Von Minckwitz G, Whelan T, Winer E, Wiang X, Wang Y, Wood W (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135.  https://doi.org/10.1016/S0140-6736(14)60488-8 CrossRefGoogle Scholar
  18. 18.
    Hille-Betz U, Vaske B, Bremer M, Soergel P, Kundu S, Klapdor R, Hillemanns P, Henkenberens C (2016) Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy. Strahlenther Onkol 192(1):8–16.  https://doi.org/10.1007/s00066-015-0899-y CrossRefGoogle Scholar
  19. 19.
    Corradini S, Ballhausen H, Weingandt H, Freislederer P, Schönecker S, Niyazi M, Simonetto C, Eidemüller M, Ganswindt U, Belka C (2018) Left-sided breast cancer and risks of secondary lung cancer and ischemic heart disease. Strahlenther Onkol 194(3):196–205.  https://doi.org/10.1007/s00066-017-1213-y CrossRefGoogle Scholar
  20. 20.
    Jardel P, Vignot S, Cutuli B, Creisson A, Vass S, Barranger E, Thariat J (2018) Should Adjuvant radiation therapy be systematically proposed for male breast cancer? A systematic review. Anticancer Res 38(1):23–31.  https://doi.org/10.21873/anticanres.12187 Google Scholar
  21. 21.
    Eggemann H, Ignatov A, Stabenow R, Von Minckwitz G, Röhl FW, Hass P, Costa SD (2013) Male breast cancer: 20-year survival data for post-mastectomy radiotherapy. Breast Care 8(4):270–275.  https://doi.org/10.1159/000354122 CrossRefGoogle Scholar
  22. 22.
    Abrams MJ, Koffer PP, Wazer DE, Hepel JT (2017) Postmastectomy radiation therapy is associated with improved survival in node-positive male breast cancer: a population analysis. Int J Radiat Oncol Biol Phys 98(2):384–391.  https://doi.org/10.1016/j.ijrobp.2017.02.007 CrossRefGoogle Scholar
  23. 23.
    Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2017) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.0 – Dezember 2017, 2017 AWMF Registernummer: 032-045OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/. Accessed 18 May 2018Google Scholar
  24. 24.
    Liedtke C, Thill M, Jackisch C, Thomssen C, Müller V, Janni W (2017) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2017. Breast Care 12(3):172–183CrossRefGoogle Scholar
  25. 25.
    Nahleh ZA, Srikantiah R, Safa M, Jazieh A‑R, Muhleman A, Komrokji R (2007) Male breast cancer in the veterans affairs population. Cancer 109(8):1471–1477.  https://doi.org/10.1002/cncr.22589 CrossRefGoogle Scholar
  26. 26.
    Scott-Conner CEH, Jochimsen PR, Menck HR, Winchester DJ (1999) An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 126(4):775–781.  https://doi.org/10.1016/S0039-6060(99)70135-2 CrossRefGoogle Scholar
  27. 27.
    Donegan WL, Redlich PN, Lang PJ, Gall MT (1998) Carcinoma of the breast in males: a multiinstitutional survey. Cancer 83(3):498–509CrossRefGoogle Scholar
  28. 28.
    Chakravarthy A, Kim CR (2002) Post-mastectomy radiation in male breast cancer. Radiother Oncol 65(2):99–103CrossRefGoogle Scholar
  29. 29.
    Macdonald G, Paltiel C, Olivotto IA, Tyldesley S (2005) A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol 16(9):1442–1448.  https://doi.org/10.1093/annonc/mdi274 CrossRefGoogle Scholar
  30. 30.
    Salas M, Hofman A, Stricker BH (1999) Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 149(11):981–983CrossRefGoogle Scholar
  31. 31.
    Müller AC, Gani C, Rehm HM, Eckert F, Bamberg M, Hehr T, Weinmann M (2012) Are there biologic differences between male and female breast cancer explaining inferior outcome of men despite equal stage and treatment?! Strahlenther Onkol 188(9):782–787.  https://doi.org/10.1007/s00066-012-0118-z CrossRefGoogle Scholar
  32. 32.
    Hong JH, Ha KS, Jung YH, Won HS, An HJ, Lee GJ, Kang D, Park JC, Park S, Byun JH, Suh YJ, Kim JS, Park WC, Jung SS, Park IY, Chung SM, Woo IS (2016) Clinical features of male breast cancer: Experiences from seven institutions over 20 years. Cancer Res Treat 48(4):1389–1398.  https://doi.org/10.4143/crt.2015.410 CrossRefGoogle Scholar
  33. 33.
    Arslan UY, Oksuzoglu B, Ozdemir N, Aksoy S, Alkis N, Gok A, Kaplan MA, Gumus M, Berk V, Uncu D, Baykara M, Colak D, Uyeturk U, Turker I, Isikdogan A (2012) Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol 29(2):554–560.  https://doi.org/10.1007/s12032-011-9978-9 CrossRefGoogle Scholar
  34. 34.
    Meattini I, Livi L, Franceschini D, Saieva C, Scotti V, Casella D, Criscenti V, Zanna I, Meacci F, Gerlain E, Agresti B, Mangoni M, Paiar F, Simontacchi G, Greto D, Nori J, Bianchi S, Cataliotti L, Biti G (2013) Treatment of invasive male breast cancer: a 40-year single-institution experience. Radiol Med 118(3):476–486.  https://doi.org/10.1007/s11547-012-0867-x CrossRefGoogle Scholar
  35. 35.
    Madden NA, Macdonald OK, Call JA, Schomas DA, Lee CM, Patel S (2016) Radiotherapy and Male breast cancer: a population-based registry analysis. Am J Clin Oncol 39(5):458–462.  https://doi.org/10.1097/coc.0000000000000078 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Paul Rogowski
    • 1
  • Stephan Schönecker
    • 1
  • Montserrat Pazos
    • 1
  • Daniel Reitz
    • 1
  • Michael Braun
    • 2
  • Martin Pölcher
    • 2
  • Claus Hanusch
    • 2
  • Rachel Wuerstlein
    • 3
    • 4
  • Nadia Harbeck
    • 3
    • 4
  • Sven Mahner
    • 3
    • 4
  • Claus Belka
    • 1
    • 4
  • Stefanie Corradini
    • 1
    Email author
  1. 1.Department of Radiation Oncology, University HospitalLMU MunichMunichGermany
  2. 2.Red Cross Breast CenterMunichGermany
  3. 3.Breast Center at the Department of Obstetrics and GynecologyLMU MunichMunichGermany
  4. 4.Comprehensive Cancer Center (CCC-LMU), University HospitalLMU MunichMunichGermany

Personalised recommendations